HK Stock MarketDetailed Quotes

09688 ZAI LAB

20.800 -1.150-5.24%
Not Open 11/29 16:08 CST

About ZAI LAB Company

Zaiding Pharmaceutical is an innovative biopharmaceutical company based in China and operating globally. It is committed to providing innovative drugs in the fields of cancer, autoimmune and infectious diseases to patients in China and around the world. Zaiding Pharmaceutical is headquartered in Shanghai. Since its establishment in 2014, it has established partnerships with many of the world's leading biopharmaceutical companies to create a broad line of late-stage innovative drug candidates. For global biopharmaceutical companies seeking to enter the Chinese market and find long-term strategic partners for international clinical development, Zaiding Pharmaceutical has become one of the most trustworthy partner candidates in the industry through a series of successful cooperation cases. Through these successful collaborations, Zaiding Pharmaceutical has built the most powerful advanced oncology product pipeline among innovative Chinese biotechnology companies, with many of the world's first of its kind and/or best-in-class drugs. At the same time, we are continuously improving our in-house R&D capabilities to further supplement our product line, with the goal of having 1-2 global new drug clinical trial applications (IND) each year in the future. Zaiding Pharmaceutical is rapidly developing into a fully integrated biopharmaceutical company that discovers, develops, produces and commercializes innovative medicines in China and around the world. To this end, we have set up an internal R&D center in China to promote drug research and development, built a strong clinical development and operation team, and established our own production base. Additionally, we have set up a specialized commercial team to support the promotion of innovative products in China. We believe that this integration strategy will provide Zaiding Pharmaceutical with a sustainable competitive advantage. Zaiding Pharmaceutical was successfully listed on the US NASDAQ in September 2017. Since then, the company has developed rapidly, set up branches or offices in many parts of China, and established an American headquarters in San Francisco in December 2018. As of December 2019, the company had around 700 employees worldwide.

Company Profile

Company NameZAI LAB
Listing Date09/28/2020
Issue Price562.00
Shares Offered10.56M share
RegistrationCayman Islands
ChairmanYing Du
SecretaryLini\f. ty edmondson Ouyang
Audit InstitutionKPMG LLP, KPMG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeHarbour Place 2nd Floor 103 South Church Street P.O. Box 472 George Town Grand Cayman KY1-1106 Cayman Islands
Head Office and Principal Place of BusinessRoom 2301, 23rd floor, Hong Kong Transport Tower, 510 King's Road, North Point, Hong Kong
Fiscal Year Ends12-31
MarketHong Kong motherboard
Business Zai Lab Ltd is a holding company mainly engaged in biopharmaceuticals. The company is dedicated to the discovery, development, and commercialization of proprietary therapies to address a large number of unmet medical needs in the Chinese market, including oncology, autoimmunity, and infectious diseases. The company has a range of patent candidates from the discovery phase to the later stages of clinical projects. These include Niraparib (ZL-2306), ZL-2103, and ZL-1101.

Company Executives

  • Name
  • Position
  • Salary
  • Ying Du
  • Director,Chairman,CEO,Authorized Representative
  • 11.14M
  • John D. Diekman
  • Audit Committee Member,Remuneration Committee Member,Nomination Committee Member,Independent Director
  • --
  • Kaixian Chen
  • Independent Director
  • 556.00K
  • Richard Gaynor
  • Independent Director
  • 311.00K
  • Yingyu Liang
  • Independent Director
  • --
  • William Lis
  • Independent Director,Nomination Committee Member
  • 561.00K
  • Scott W. Morrison
  • Audit Committee Chairman,Independent Director
  • 314.00K
  • Leon O. Moulder, Jr.
  • Independent Director,Remuneration Committee Member,Nomination Committee Chairman
  • 568.00K
  • Michel Pericles Vounatsos
  • Independent Non-Executive Director
  • --
  • Peter Wirth
  • Independent Director,Audit Committee Member,Remuneration Committee Chairman
  • 575.00K
  • Yajing Chen
  • CFO
  • --
  • Rafael G.Amado
  • Head of Global Oncology Development
  • --
  • F. Ty Edmondson
  • Joint Company Secretary,Chief Legal Officer
  • --
  • Harald Reinhart
  • President, Head of Global Development in the Central Nervous System, Autoimmunity, and Anti-Infection
  • --
  • Joshua Smiley
  • Chief Operating Officer,President
  • --
  • Tao Fu
  • Chief Strategy Officer
  • --
  • Lini Ouyang
  • Authorized Representative,Joint Company Secretary
  • --
Paper Trade Start
LMT Order
Claim up to $1 million virtual fund, join moomoo paper trading today! Claim Now >